Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

SGLT2 (for “Sodium GLucose coTransporter” protein 2) is the major protein responsible for glucose reabsorption in the kidney and its inhibition has been the focus of drug discovery efforts to treat type 2 diabetes. In order to better clarify the human tissue distribution of expression of SGLT2 and related members of this cotransporter class, we performed TaqMan™ (Applied Biosystems, Foster City, CA, USA) quantitative polymerase chain reaction (PCR) analysis of SGLT2 and other sodium/glucose transporter genes on RNAs from 72 normal tissues from three different individuals. We consistently observe that SGLT2 is highly kidney specific while SGLT5 is highly kidney abundant; SGLT1, sodium-dependent amino acid transporter (SAAT1), and SGLT4 are highly abundant in small intestine and skeletal muscle; SGLT6 is expressed in the central nervous system; and sodium myoinositol cotransporter is ubiquitously expressed across all human tissues.

• Publication year

  2010

• Venue

  Diabetes Therapy

• Publication date

  2010-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s13300-010-0006-4PMID 22127746PMCID 3138482
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo

  2011cited by this paper
• Sodium–glucose transport: role in diabetes mellitus and potential clinical implications

  2010cited by this paper
• SGLT2 mediates glucose reabsorption in the early proximal tubule

  2010cited by this paper
• Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

  2010cited by this paper
• Functional expression of SGLTs in rat brain.

  2010cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• ROOT UV-B SENSITIVE2 Acts with ROOT UV-B SENSITIVE1 in a Root Ultraviolet B-Sensing Pathway1[C][OA]

  2009cited by this paper
• BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources

  2009cited by this paper
• Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.

  2009cited by this paper
• Role of root UV-B sensing in Arabidopsis early seedling development

  2008cited by this paper
• Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

  2008cited by this paper
• Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody.

  2008cited by this paper
• Expression and functionality of the Na+/myo-inositol cotransporter SMIT2 in rabbit kidney.

  2007cited by this paper
• The sodium-dependent glucose cotransporter SLC5A11 as an autoimmune modifier gene in SLE.

  2007cited by this paper
• Active sugar transport in health and disease

  2007cited by this paper
• Inhibitory effect of HIV-1 Tat protein on the sodium-D-glucose symporter of human intestinal epithelial cells

  2006cited by this paper
• GAPDH as a housekeeping gene: analysis of GAPDH mRNA expression in a panel of 72 human tissues.

  2005cited by this paper
• SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose.

  2005cited by this paper
• Localization of the Na+-d-glucose cotransporter SGLT1 in the blood-brain barrier

  2004cited by this paper
• The sodium/glucose cotransport family SLC5

  2004cited by this paper
• Specific Cre/Lox recombination in the mouse proximal tubule.

  2004cited by this paper
• Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)

  2003cited by this paper
• A glucose sensor hiding in a family of transporters

  2003cited by this paper
• The sodium/glucose cotransport family SLC5

  2003cited by this paper
• Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences

  2002cited by this paper
• Identification of a Novel Na+/myo-Inositol Cotransporter*

  2002cited by this paper
• New human sodium/glucose cotransporter gene (KST1): identification, characterization, and mutation analysis in ICCA (infantile convulsions and choreoathetosis) and BFIC (benign familial infantile convulsions) families.

  2002cited by this paper
• Expression of the Na+‐d‐Glucose Cotransporter SGLT1 in Neurons

  1997cited by this paper
• Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption

  1996cited by this paper
• Ion specificity and stoichiometry of the cardiac inositol transporter.

  1995cited by this paper
• Molecular Characteristics of Na+-coupled Glucose Transporters in Adult and Embryonic Rat Kidney *

  1995cited by this paper
• The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21.

  1995cited by this paper
• The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

  1994cited by this paper
• The high affinity Na+/glucose cotransporter. Re-evaluation of function and distribution of expression.

  1994cited by this paper
• SAAT1 is a low affinity Na+/glucose cotransporter and not an amino acid transporter. A reinterpretation.

  1994cited by this paper
• Cloning and expression of a mammalian Na+/amino acid cotransporter with sequence similarity to Na+/glucose cotransporters.

  1993cited by this paper
• Identification of two unique polypeptides from dog kidney outer cortex and outer medulla that exhibit different Na+/D-glucose cotransport functional properties.

  1993cited by this paper
• Cloning of a human kidney cDNA with similarity to the sodium-glucose cotransporter.

  1992cited by this paper
• Expression cloning and cDNA sequencing of the Na+/glucose co-transporter

  1987cited by this paper

• Dapagliflozin lowers blood pressure via regulating the sympathetic neural activity in the paraventricular nucleus of hypothalamus in normal mice

  2026cites this paper
• Advances in Intestinal Glucose Absorption Regulation for Ruminant Energy Efficiency Improvement.

  2026cites this paper
• Empagliflozin Attenuates Cardiac Fibrosis by Suppressing Fibroblast-Mediated C-C Motif Chemokine Ligand 2 Expression.

  2026cites this paper
• High-Fructose-Induced Salt-Sensitive Hypertension: The Potential Benefit of SGLT4 or SGLT5 Modulation

  2025influential citation
• Recent Progress in Analytical Method Development and Validation of Dapagliflozin

  2025influential citation
• Upper-gastrointestinal tract metabolite profile regulates glycaemic and satiety responses to meals with contrasting structure: a pilot study

  2025cites this paper
• Comparison of the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiac Fibroblast Properties

  2025cites this paper
• Antiarrhythmic Potential of SGLT2 Inhibitors: Mechanistic Insights and Clinical Evidence.

  2025cites this paper
• Expression of GLUT-1 and SGLT-2 in the Chorioretina of Streptozotocin-induced Diabetic Rats After Administration of Empagliflozin

  2025cites this paper
• Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes

  2025cites this paper
• The SGLT2 inhibitor empagliflozin promotes increased fatty acid oxidation in skeletal muscle cells

  2025cites this paper
• Treatment Progress of SGLT2 Inhibitors in Anemia of CKD

  2025cites this paper
• Parkinson's disease and glucose metabolism impairment

  2025cites this paper
• Empagliflozin beyond antidiabetic effect: Amelioration of cyclophosphamide-induced testicular toxicity in rats: Orchestrating klotho/Nrf-2/PPAR-γ/NF-κB/ Bax/Bcl-2 cues.

  2025cites this paper
• Cardiovascular therapeutic targets of sodium-glucose co-transporter 2 (SGLT2) inhibitors beyond heart failure.

  2025cites this paper
• Sotagliflozin: Two Birds with One Stone?

  2025cites this paper
• Envisioning Glucose Transporters (GLUTs and SGLTs) as Novel Intervention against Cancer: Drug Discovery Perspective and Targeting Approach.

  2024cites this paper
• The relationship between SGLT2 and systemic blood pressure regulation

  2024cites this paper
• SGLT2 inhibitors: how do they affect the cardiac cells

  2024cites this paper
• SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system

  2024cites this paper
• Sympathetic Activation Promotes Sodium Glucose Co-Transporter-1 Protein Expression in Rodent Skeletal Muscle

  2024cites this paper
• Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors and Cardiovascular Outcomes: A Review of Literature

  2024cites this paper
• Protective Influence of SGLT-2 Inhibitors Against Heart Failure in Type 2 Diabetes Mellitus Through Longitudinal Clinical Database Analysis

  2024cites this paper
• Neurodevelopment Is Dependent on Maternal Diet: Placenta and Brain Glucose Transporters GLUT1 and GLUT3

  2024cites this paper
• SGLT2i Alleviates Atherosclerosis by Inhibiting NHE1 Activation to Protect against Macrophage Senescence Induced by Angiotensin II.

  2024cites this paper
• Uric acid in diabetic microvascular complications: Mechanisms and therapy.

  2024cites this paper
• Cardioprotective Effects of Sodium-Glucose Cotransporter Subtype Inhibition on Ischemic and Pharmacological Preconditioning

  2024cites this paper
• Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis

  2024cites this paper
• SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

  2024cites this paper
• SGLT2 Inhibitors: Paradigm Shift from Diabetes Care to Metabolic Care—An Indian Perspective

  2024cites this paper
• Efficacy and Safety of SGLT2 Inhibitors in Pediatric Patients and Young Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Guardians against Mitochondrial Dysfunction and Endoplasmic Reticulum Stress in Heart Diseases

  2024cites this paper
• The Off-Target Cardioprotective Mechanisms of Sodium–Glucose Cotransporter 2 Inhibitors: An Overview

  2024cites this paper
• Effects of empagliflozin on reproductive system in men without diabetes

  2024cites this paper
• Doxorubicin‑induced cardiomyopathy is mitigated by empagliflozin via the modulation of endoplasmic reticulum stress pathways

  2024cites this paper
• In nondiabetic C57BL/6J mice, canagliflozin affects the skeleton in a sex- and age-dependent manner

  2024cites this paper
• Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?

  2024cites this paper
• Canagliflozin exerts anti-inflammatory and antioxidant effects in the heart and skin tissues: Biochemical and histopathological assessment in a model of accelerated aging induced by D-galactose in mice

  2024cites this paper
• In vivo assessment of safety, biodistribution, and radiation dosimetry of the [18F]Me4FDG PET-radiotracer in adults

  2024cites this paper
• Extrarenal benefits of SGLT2 inhibitors in the treatment of cardiomyopathy.

  2024cites this paper
• Endothelial Protection by Sodium-Glucose Cotransporter 2 Inhibitors: A Literature Review of In Vitro and In Vivo Studies

  2024cites this paper
• Possible mechanism of effect of the empagliflozin on cardiovascular mortality

  2024cites this paper
• SGLT1 contributes to glucose-mediated exacerbation of ischemia–reperfusion injury in ex vivo rat heart

  2024cites this paper
• The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms

  2023cites this paper
• The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus

  2023cites this paper
• The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance

  2023cites this paper
• Strain differences in the drug transport capacity of intestinal glucose transporters in Sprague-Dawley versus Wistar rats, C57BL/6J versus Kunming mice.

  2023cites this paper
• Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling

  2023cites this paper
• 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action

  2023cites this paper
• Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials

  2023cites this paper
• Obesity-associated cardiometabolic complications in polycystic ovary syndrome: The potential role of sodium-glucose cotransporter-2 inhibitors

  2023cites this paper
• 2-Deoxy-glucose ameliorates the peritoneal mesothelial and endothelial barrier function perturbation occurring due to Peritoneal Dialysis fluids exposure.

  2023cites this paper
• Protective Effect of Ipragliflozin on Acute Brain Injury Induced by Endotoxemia in Mice

  2023cites this paper
• Predictive Potential of Biomarkers of Intestinal Barrier Function for Therapeutic Management with Teduglutide in Patients with Short Bowel Syndrome

  2023cites this paper
• Dapagliflozin Alleviates Myocardial Ischaemia Reperfusion Injury by Activating Mitophagy via the AMPK-PINK1/Parkin Signalling Pathway.

  2023cites this paper
• A randomized double-blind phase Ib clinical trial of SY-009 in patients with type 2 diabetes mellitus.

  2023cites this paper
• SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast

  2023cites this paper
• 1,5-Anhydro-D-Fructose Exhibits Satiety Effects via the Activation of Oxytocin Neurons in the Paraventricular Nucleus

  2023cites this paper
• A systematic overview of bexagliflozin: A type 2 diabetic drug

  2023cites this paper
• Dapagliflozin modulates neuronal injury via instigation of LKB1/p-AMPK/GABAB R2 signaling pathway and suppression of the inflammatory cascade in an essential tremor rat model

  2023cites this paper
• Hyperglycemic exacerbation of myocardial infarction through SGLT1 - a glucose paradox.

  2023cites this paper
• SGLT2 Inhibition in Heart Failure with Preserved Ejection Fraction — The New Frontier

  2023cites this paper
• Integrated analysis reveals ceRNA network of cardiac remodeling by SGLT2 inhibitor in middle-aged hypertensive rats.

  2023cites this paper
• A bal kamrai miokardiális nátrium-glükóz-kotranszporter-1-expresszió vizsgálata végstádiumú szívelégtelenségben

  2023cites this paper
• Sodium-Glucose Cotransporter-2 Inhibition Benefits in Cardiorenal Risk in Men and Women

  2022cites this paper
• SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives

  2022cites this paper
• Comparative evaluation new glucagon-like peptide 1 receptor agonist semaglutide and sodium-glucose cotransporter-2 inhibitors empagliflozin on left ventricular diastolic function in patients with arterial hypertension, obesity and type 2 diabetes mellitus

  2022cites this paper
• Ketones: the double-edged sword of SGLT2 inhibitors?

  2022cites this paper
• Influence of SGLT2 Inhibitors in Remodeling, Substrate and Ion Metabolism of Myocardium to Prevent Cardiovascular Risks: Recent Work and Advancement.

  2022cites this paper
• Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism

  2022cites this paper
• Coronary Microvascular Dysfunction in Diabetes Mellitus: Pathogenetic Mechanisms and Potential Therapeutic Options

  2022cites this paper
• Glycemic Control and the Heart: The Tale of Diabetic Cardiomyopathy Continues

  2022cites this paper
• Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study

  2022cites this paper
• Regional epithelial cell diversity in the small intestine of pigs.

  2022cites this paper
• Successful treatment of imatinib-induced periorbital edema with a sodium-glucose cotransporter-2 inhibitor

  2022cites this paper
• Getting sweeter: new evidence for glucose transporters in specific cell types of the airway?

  2022cites this paper
• Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis

  2022cites this paper
• The Relationship Between the Blood-Brain-Barrier and the Central Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors

  2022cites this paper
• Sodium-Glucose Cotransporter-2 (SGLT2) expression in diabetic and non-diabetic failing human cardiomyocytes.

  2022cites this paper
• Putative protective effects of sodium-glucose cotransporter 2 inhibitors on atrial fibrillation through risk factor modulation and off-target actions: potential mechanisms and future directions

  2022cites this paper
• DMSO_A_375559 2583..2597

  2022cites this paper
• Effect of Sodium-Glucose Co-transporter Protein 2 Inhibitors on Arrhythmia in Heart Failure Patients With or Without Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• The Current Evolutions in the Pharmacotherapeutic Management of Heart Failure

  2022cites this paper
• in Comparative effects of sodium–glucose cotransporter 2 inhibitors on electrolyte in patients with type 2 diabetes

  2022cites this paper
• SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart

  2022cites this paper
• Empagliflozin Ameliorates Diabetic Cardiomyopathy via Attenuating Oxidative Stress and Improving Mitochondrial Function

  2022cites this paper
• Exenatide and Dapagliflozin Combination Enhances Sertoli Cell Secretion of Key Metabolites for Spermatogenesis

  2022cites this paper
• Inositols in the ovaries: activities and potential therapeutic applications

  2022cites this paper
• Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin

  2022cites this paper
• Cellular interplay between cardiomyocytes and non-myocytes in diabetic cardiomyopathy

  2022cites this paper
• Regulation of Glucose Insulinotropic Peptide and Intestinal Glucose Transporters in the Diet-Induced Obese Mouse

  2022cites this paper
• Empagliflozin Ameliorates Ouabain-Induced Na^+ and Ca^2+ Dysregulations in Ventricular Myocytes in an Na^+-Dependent Manner

  2022cites this paper
• Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Who Underwent Surgery for Pancreatic Carcinoma: A Case Report

  2022cites this paper
• Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice

  2022cites this paper
• An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors

  2022cites this paper
• Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Serum Electrolyte Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Randomized Controlled Trials

  2022cites this paper
• Diabetes mellitus and multiple myeloma; common features of two distinct entities

  2022cites this paper
• Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials

  2021cites this paper
• SGLT2 inhibitors as calorie restriction-mimetics: insights on longevity pathways and age-related diseases.

  2021cites this paper
• Central administration of sodium-glucose cotransporter-2 inhibitors increases food intake involving adenosine monophosphate-activated protein kinase phosphorylation in the lateral hypothalamus in healthy rats

  2021cites this paper